Avicanna Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVCNF research report →
Companywww.avicanna.com
Avicanna Inc. , a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions.
- CEO
- Aras Azadian Mba
- IPO
- 2021
- Employees
- 87
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $12.58M
- P/E
- -4.31
- P/S
- 0.63
- P/B
- 4.00
- EV/EBITDA
- -6.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.34%
- Op Margin
- -12.95%
- Net Margin
- -13.90%
- ROE
- -116.09%
- ROIC
- -25.02%
Growth & Income
- Revenue
- $25.46M · -0.01%
- Net Income
- $-2,841,896 · 21.44%
- EPS
- $-0.02 · 31.49%
- Op Income
- $-2,713,780
- FCF YoY
- 51.32%
Performance & Tape
- 52W High
- $0.24
- 52W Low
- $0.09
- 50D MA
- $0.11
- 200D MA
- $0.16
- Beta
- 1.24
- Avg Volume
- 73.63K
Get TickerSpark's AI analysis on AVCNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AVCNF Coverage
We haven't published any research on AVCNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVCNF Report →